MR指纹技术与ADC图在前列腺移行带病灶表征中的应用
回顾性分析67例男性75个移行带可疑病灶,评估MR指纹技术联合ADC图区分正常移行带、癌与非癌、临床显著癌与不显著病灶及PI-RADS 3类病灶的价值;结果显示联合T1与ADC的AUC分别为0.94、0.81,T1区分PI-RADS 3类病灶AUC为0.79,提示可能改善移行带病灶表征。
要点
- 移行带癌的T1、T2、ADC均低于正常移行带(P < .001)。
- 癌的T1、T2、ADC低于非癌(T1与ADC P = .001,T2 P = .03)。
- T1联合ADC区分癌与非癌的AUC为0.94,区分临床显著癌与不显著病灶的AUC为0.81。
核心结论
- 基于MR指纹技术的弛豫测量联合ADC图可能改善移行带病灶的表征。
研究设计与样本
- 单中心大学医院回顾性分析,2014年9月至2018年8月纳入67例男性75个移行带可疑病灶,均行T2WI、ADC图(b值50-1400 sec/mm2)、稳态自由进动MR指纹技术及靶向活检(60例MRI机架内、15例认知融合靶向)。
关键影像表现/征象
- 正常移行带T1为1800 msec ± 150、T2为65 msec ± 22、ADC为(1.13 ± 0.19)× 10-3 mm2/sec,均高于癌的1450 msec ± 110、36 msec ± 11、(0.57 ± 0.13)× 10-3 mm2/sec(P < .001)。
- 癌的T1、T2、ADC低于非癌的1620 msec ± 120、47 msec ± 16、(0.82 ± 0.13)× 10-3 mm2/sec(T1与ADC P = .001,T2 P = .03)。
- 临床显著癌(Gleason评分≥7)的T1为1440 msec ± 140、ADC为(0.58 ± 0.14)× 10-3 mm2/sec,低于临床不显著病灶的1580 msec ± 120、(0.75 ± 0.17)× 10-3 mm2/sec(P = .001)。
- PI-RADS 3类病灶中,癌的T1为1430 msec ± 220、ADC为(0.60 ± 0.17)× 10-3 mm2/sec,低于非癌的1630 msec ± 120、(0.81 ± 0.13)× 10-3 mm2/sec(T1 P = .006,ADC P = .004)。
诊断标准与关键数值
- T1联合ADC区分癌与非癌的AUC为0.94。
- T1联合ADC区分临床显著癌与临床不显著病灶的AUC为0.81。
- T1区分PI-RADS 3类病灶中癌与非癌的AUC为0.79。
临床应用与阅片要点
- 移行带可疑病灶中,癌的T1、T2、ADC均低于正常移行带,T1联合ADC可能有助于区分癌与非癌。
- 临床显著癌的T1、ADC低于临床不显著病灶,T1联合ADC可能有助于区分两者。
- PI-RADS 3类病灶中,T1、ADC较低者更可能为癌,T1的AUC为0.79。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundPreliminary studies have shown that MR fingerprinting-based relaxometry combined with apparent diffusion coefficient (ADC) mapping can be used to differentiate normal peripheral zone from prostate cancer and prostatitis. The utility of relaxometry and ADC mapping for the transition zone (TZ) is unknown.PurposeTo evaluate the utility of MR fingerprinting combined with ADC mapping for characterizing TZ lesions.Materials and MethodsTZ lesions that were suspicious for cancer in men who underwent MRI with T2-weighted imaging and ADC mapping (b values, 50-1400 sec/mm2), MR fingerprinting with steady-state free precession, and targeted biopsy (60 in-gantry and 15 cognitive targeting) between September 2014 and August 2018 in a single university hospital were retrospectively analyzed. Two radiologists blinded to Prostate Imaging Reporting and Data System (PI-RADS) scores and pathologic diagnosis drew regions of interest on cancer-suspicious lesions and contralateral visually normal TZs (NTZs) on MR fingerprinting and ADC maps. Linear mixed models compared two-reader means of T1, T2, and ADC. Generalized estimating equations logistic regression analysis was used to evaluate both MR fingerprinting and ADC in differentiating NTZ, cancers and noncancers, clinically significant (Gleason score ≥ 7) cancers from clinically insignificant lesions (noncancers and Gleason 6 cancers), and characterizing PI-RADS version 2 category 3 lesions.ResultsIn 67 men (mean age, 66 years ± 8 [standard deviation]) with 75 lesions, targeted biopsy revealed 37 cancers (six PI-RADS category 3 cancers and 31 PI-RADS category 4 or 5 cancers) and 38 noncancers (31 PI-RADS category 3 lesions and seven PI-RADS category 4 or 5 lesions). The T1, T2, and ADC of NTZ (1800 msec ± 150, 65 msec ± 22, and [1.13 ± 0.19] × 10-3 mm2/sec, respectively) were higher than those in cancers (1450 msec ± 110, 36 msec ± 11, and [0.57 ± 0.13] × 10-3 mm2/sec, respectively; P < .001 for all). The T1, T2, and ADC in cancers were lower than those in noncancers (1620 msec ± 120, 47 msec ± 16, and [0.82 ± 0.13] × 10-3 mm2/sec, respectively; P = .001 for T1 and ADC and P = .03 for T2). The area under the receiver operating characteristic curve (AUC) for T1 plus ADC was 0.94 for separation. T1 and ADC in clinically significant cancers (1440 msec ± 140 and [0.58 ± 0.14] × 10-3 mm2/sec, respectively) were lower than those in clinically insignificant lesions (1580 msec ± 120 and [0.75 ± 0.17] × 10-3 mm2/sec, respectively; P = .001 for all). The AUC for T1 plus ADC was 0.81 for separation. Within PI-RADS category 3 lesions, T1 and ADC of cancers (1430 msec ± 220 and [0.60 ± 0.17] × 10-3 mm2/sec, respectively) were lower than those of noncancers (1630 msec ± 120 and [0.81 ± 0.13] × 10-3 mm2/sec, respectively; P = .006 for T1 and P = .004 for ADC). The AUC for T1 was 0.79 for differentiating category 3 lesions.ConclusionMR fingerprinting-based relaxometry combined with apparent diffusion coefficient mapping may improve transition zone lesion characterization.© RSNA, 2019Online supplemental material is available for this article.
引用
- Panda A, Obmann VC, Lo WC, et al. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland. Radiology. 2019. PMID: 31335285. doi:10.1148/radiol.2019181705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。